Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board

Rhea-AI Summary

Teligent, Inc. (Nasdaq: TLGT) has appointed John Celentano as the new Chairman of its Board of Directors, succeeding James C. Gale, who has chosen not to seek reelection. Celentano, who joined the board in March 2015, brings extensive experience from Bristol-Myers Squibb, where he held various leadership roles. He also remains a member of Teligent's Compensation and Audit Committees. The company expresses excitement about leveraging Celentano's pharmaceutical expertise to drive future growth.

Positive

• John Celentano's extensive experience in the pharmaceutical industry.
• Fresh leadership perspectives with Celentano as Chairman.

Negative

• James C. Gale's departure may raise concerns about board continuity.

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent's Board of Directors, replacing James C. Gale who opted to not stand for reelection to Teligent’s board of directors in order to devote more time to other business interests.

Mr. Celentano joined Teligent as a director in March 2015.  He will also continue to serve as a member of Teligent's Compensation and Audit Committees.

Previously, Mr. Celentano held key senior leadership positions with Bristol-Myers Squibb Company including: President, Bristol-Myers Squibb Healthcare Group (Mead Johnson Nutrition, ConvaTec, and Medical Imaging); Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada, and UK/Northern Europe; Senior Vice President of Human Resources, Public Affairs and Philanthropy; and Senior Vice President of Strategy and Productivity.

While at Bristol-Myers, Mr. Celentano was an active participant in the development of their biopharma strategy and led major initiatives on productivity transformation, streamlining operations to support the company’s growth opportunities. Mr. Celentano currently works as an independent senior advisor and serves on the Board of privately held YourEncore Inc. He holds a B.A. from the University of Delaware and an MBA from Drexel University.

"We are excited to leverage John’s broad, extensive experience in the pharmaceutical industry and proven boardroom leadership in the role of Chairman of Teligent’s Board of Directors," said Timothy B. Sawyer, Teligent's President and CEO.  "We look forward to working closely with John as our new Chairman and the Board joins me in thanking Jim Gale for his service and wishing him well as he focuses on his private endeavors."

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Contact:

Damian Finio
Teligent, Inc.
856-336-9117
www.teligent.com

FAQ

Who is the new Chairman of Teligent?

John Celentano has been appointed as the new Chairman of Teligent's Board of Directors.

Why did James C. Gale not seek reelection as Chairman?

James C. Gale opted not to stand for reelection to focus more on other business interests.

What prior experience does John Celentano have?

John Celentano held key senior leadership positions at Bristol-Myers Squibb, including President of the Healthcare Group.

What committees will John Celentano serve on at Teligent?

He will continue to serve on Teligent's Compensation and Audit Committees.

How does Teligent view John Celentano's appointment?

Teligent is excited to leverage Celentano's experience and leadership in the pharmaceutical industry.